 | • レポートコード：MRC2303F0007 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、253ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医療 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の本調査レポートでは、2021年に209.8億ドルであった世界の治験用供給＆物流市場規模が、2022年に225.9億ドルになり、2027年まで年平均7.69%で成長して327.4億ドルに拡大すると予測しています。本レポートは、治験用供給＆物流の世界市場について調べ、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、サービス別（コンパレータソーシング、物流・流通、製造、包装・盲検化・ラベリング、保管・保存）分析、種類別（生物学的製剤、医療機器、低分子化合物）分析、フェーズ別（BA/BE研究、フェーズ1、フェーズ2、フェーズ3、フェーズ4）分析、治療領域別（血液疾患、心血管系疾患、中枢神経系・精神疾患、皮膚疾患、その他）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報などを以下の構成でまとめております。また、Almac Group、Ancillare, LP、Biocair International Limited、Catalent, Inc.、Clinigen Group PLC、Eurofins Scientific Group、ICON PLC、Infosys Limitedなどの企業情報が含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の治験用供給＆物流市場規模：サービス別 - コンパレータソーシングにおける市場規模 - 物流・流通における市場規模 - 製造における市場規模 - 包装・盲検化・ラベリングにおける市場規模 - 保管・保存における市場規模 ・世界の治験用供給＆物流市場規模：種類別 - 生物学的製剤の市場規模 - 医療機器の市場規模 - 低分子化合物の市場規模 ・世界の治験用供給＆物流市場規模：フェーズ別 - BA/BE研究における市場規模 - フェーズ1における市場規模 - フェーズ2における市場規模 - フェーズ3における市場規模 - フェーズ4における市場規模 ・世界の治験用供給＆物流市場規模：治療領域別 - 血液疾患における市場規模 - 心血管系疾患における市場規模 - 中枢神経系・精神疾患における市場規模 - 皮膚疾患における市場規模 - その他における市場規模 ・世界の治験用供給＆物流市場規模：地域別 - 南北アメリカの治験用供給＆物流市場規模 アメリカの治験用供給＆物流市場規模 カナダの治験用供給＆物流市場規模 ブラジルの治験用供給＆物流市場規模 … - アジア太平洋の治験用供給＆物流市場規模 日本の治験用供給＆物流市場規模 中国の治験用供給＆物流市場規模 インドの治験用供給＆物流市場規模 韓国の治験用供給＆物流市場規模 台湾の治験用供給＆物流市場規模 … - ヨーロッパ/中東/アフリカの治験用供給＆物流市場規模 イギリスの治験用供給＆物流市場規模 ドイツの治験用供給＆物流市場規模 フランスの治験用供給＆物流市場規模 ロシアの治験用供給＆物流市場規模 … - その他地域の治験用供給＆物流市場規模 ・競争状況 ・企業情報 |
The Global Clinical Trial Supply & Logistics Market size was estimated at USD 20.98 billion in 2021 and expected to reach USD 22.59 billion in 2022, and is projected to grow at a CAGR 7.69% to reach USD 32.74 billion by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Clinical Trial Supply & Logistics to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Services, the market was studied across Comparator Sourcing, Logistics & Distribution, Manufacturing, Packaging, Labeling, & Blinding, and Storage & Retention. The Logistics & Distribution is further studied across Cold Chain Distribution and Non-Cold Chain Distribution.
Based on Type, the market was studied across Biologic Drugs, Medical Devices, and Small Molecules.
Based on Phase, the market was studied across BA/ BE studies, Phase 1, Phase 2, Phase 3, and Phase 4.
Based on Therapeutic Area, the market was studied across Blood Disorders, Cardiovascular Diseases, CNS & Mental Disorders, Dermatological Disorders, Digestive Disorders, ENT Diseases, Immunology, Infectious Diseases, Metabolic Disorders, Nephrology, Oncology, Rare Diseases, and Respiratory Disorders.
Based on End User, the market was studied across Contract Research Organisations (CROs), Medical Devices Companies, and Pharmaceutical & Biotechnology companies.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across Arizona, California, Florida, Illinois, New York, North Carolina, Ohio, Oregon, Pennsylvania, Tennessee, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Clinical Trial Supply & Logistics market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Clinical Trial Supply & Logistics Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Clinical Trial Supply & Logistics Market, including Almac Group, Ancillare, LP, Biocair International Limited, Catalent, Inc., Clinigen Group PLC, Eurofins Scientific Group, ICON PLC, Infosys Limited, KLIFO A/S, Liveo Research GmbH, Lonza Group AG, Marken Limited, Myonex, Inc., N-SIDE SA, Parexel International Corporation, PCI Pharma Services, Piramal Pharma Solutions, SIRO Clinpharm Private Limited, Thermo Fisher Scientific, Inc., UDG Healthcare PLC, and Walden.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Clinical Trial Supply & Logistics Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Clinical Trial Supply & Logistics Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Clinical Trial Supply & Logistics Market?
4. What is the competitive strategic window for opportunities in the Global Clinical Trial Supply & Logistics Market?
5. What are the technology trends and regulatory frameworks in the Global Clinical Trial Supply & Logistics Market?
6. What is the market share of the leading vendors in the Global Clinical Trial Supply & Logistics Market?
7. What modes and strategic moves are considered suitable for entering the Global Clinical Trial Supply & Logistics Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing Incidence of Chronic Diseases Globally
5.1.1.2. Rising Government Funds to R&D Activities
5.1.1.3. Globalization of Clinical Trials and Harmonization of Regulations
5.1.2. Restraints
5.1.2.1. High Cost Associated With the Clinical Trials
5.1.3. Opportunities
5.1.3.1. Rising Focus on Drug Development with the Launch of New Drugs
5.1.3.2. Outsourcing of Clinical Trial Activity
5.1.4. Challenges
5.1.4.1. Lack of Skilled Person to Operate Devices During Clinical Trials
5.2. Cumulative Impact of COVID-19
6. Clinical Trial Supply & Logistics Market, by Services
6.1. Introduction
6.2. Comparator Sourcing
6.3. Logistics & Distribution
6.4.1. Cold Chain Distribution
6.4.2. Non-Cold Chain Distribution
6.4. Manufacturing
6.5. Packaging, Labeling, & Blinding
6.6. Storage & Retention
7. Clinical Trial Supply & Logistics Market, by Type
7.1. Introduction
7.2. Biologic Drugs
7.3. Medical Devices
7.4. Small Molecules
8. Clinical Trial Supply & Logistics Market, by Phase
8.1. Introduction
8.2. BA/ BE studies
8.3. Phase 1
8.4. Phase 2
8.5. Phase 3
8.6. Phase 4
9. Clinical Trial Supply & Logistics Market, by Therapeutic Area
9.1. Introduction
9.2. Blood Disorders
9.3. Cardiovascular Diseases
9.4. CNS & Mental Disorders
9.5. Dermatological Disorders
9.6. Digestive Disorders
9.7. ENT Diseases
9.8. Immunology
9.9. Infectious Diseases
9.10. Metabolic Disorders
9.11. Nephrology
9.12. Oncology
9.13. Rare Diseases
9.14. Respiratory Disorders
10. Clinical Trial Supply & Logistics Market, by End User
10.1. Introduction
10.2. Contract Research Organisations (CROs)
10.3. Medical Devices Companies
10.4. Pharmaceutical & Biotechnology companies
11. Americas Clinical Trial Supply & Logistics Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Clinical Trial Supply & Logistics Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Clinical Trial Supply & Logistics Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. FPNV Positioning Matrix
14.1.1. Quadrants
14.1.2. Business Strategy
14.1.3. Product Satisfaction
14.2. Market Ranking Analysis, By Key Player
14.3. Market Share Analysis, By Key Player
14.4. Competitive Scenario
14.4.1. Merger & Acquisition
14.4.2. Agreement, Collaboration, & Partnership
14.4.3. New Product Launch & Enhancement
14.4.4. Investment & Funding
14.4.5. Award, Recognition, & Expansion
15. Company Usability Profiles
15.1. Almac Group
15.1.1. Business Overview
15.1.2. Key Executives
15.1.3. Product & Services
15.2. Ancillare, LP
15.2.1. Business Overview
15.2.2. Key Executives
15.2.3. Product & Services
15.3. Biocair International Limited
15.3.1. Business Overview
15.3.2. Key Executives
15.3.3. Product & Services
15.4. Catalent, Inc.
15.4.1. Business Overview
15.4.2. Key Executives
15.4.3. Product & Services
15.5. Clinigen Group PLC
15.5.1. Business Overview
15.5.2. Key Executives
15.5.3. Product & Services
15.6. Eurofins Scientific Group
15.6.1. Business Overview
15.6.2. Key Executives
15.6.3. Product & Services
15.7. ICON PLC
15.7.1. Business Overview
15.7.2. Key Executives
15.7.3. Product & Services
15.8. Infosys Limited
15.8.1. Business Overview
15.8.2. Key Executives
15.8.3. Product & Services
15.9. KLIFO A/S
15.9.1. Business Overview
15.9.2. Key Executives
15.9.3. Product & Services
15.10. Liveo Research GmbH
15.10.1. Business Overview
15.10.2. Key Executives
15.10.3. Product & Services
15.11. Lonza Group AG
15.11.1. Business Overview
15.11.2. Key Executives
15.11.3. Product & Services
15.12. Marken Limited
15.12.1. Business Overview
15.12.2. Key Executives
15.12.3. Product & Services
15.13. Myonex, Inc.
15.13.1. Business Overview
15.13.2. Key Executives
15.13.3. Product & Services
15.14. N-SIDE SA
15.14.1. Business Overview
15.14.2. Key Executives
15.14.3. Product & Services
15.15. Parexel International Corporation
15.15.1. Business Overview
15.15.2. Key Executives
15.15.3. Product & Services
15.16. PCI Pharma Services
15.16.1. Business Overview
15.16.2. Key Executives
15.16.3. Product & Services
15.17. Piramal Pharma Solutions
15.17.1. Business Overview
15.17.2. Key Executives
15.17.3. Product & Services
15.18. SIRO Clinpharm Private Limited
15.18.1. Business Overview
15.18.2. Key Executives
15.18.3. Product & Services
15.19. Thermo Fisher Scientific, Inc.
15.19.1. Business Overview
15.19.2. Key Executives
15.19.3. Product & Services
15.20. UDG Healthcare PLC
15.20.1. Business Overview
15.20.2. Key Executives
15.20.3. Product & Services
15.21. Walden
15.21.1. Business Overview
15.21.2. Key Executives
15.21.3. Product & Services
16. Appendix
16.1. Discussion Guide
16.2. License & Pricing